Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.

PubWeight™: 1.53‹?› | Rank: Top 4%

🔗 View Article (PMC 4481593)

Published in Blood on April 13, 2015

Authors

Kartik Sehgal1, Rituparna Das1, Lin Zhang1, Rakesh Verma1, Yanhong Deng2, Mehmet Kocoglu1, Juan Vasquez3, Srinivas Koduru1, Yan Ren4, Maria Wang4, Suzana Couto4, Mike Breider4, Donna Hansel4, Stuart Seropian5, Dennis Cooper5, Anjan Thakurta4, Xiaopan Yao6, Kavita M Dhodapkar7, Madhav V Dhodapkar8

Author Affiliations

1: Department of Medicine.
2: Yale Center for Analytic Sciences, and.
3: Department of Pediatrics, Yale University, New Haven, CT;
4: Celgene Corporation, Summit, NJ;
5: Department of Medicine, Yale Cancer Center, and.
6: Yale Center for Analytic Sciences, and Yale Cancer Center, and.
7: Department of Pediatrics, Yale University, New Haven, CT; Yale Cancer Center, and.
8: Department of Medicine, Yale Cancer Center, and Department of Immunobiology, Yale University, New Haven, CT.

Associated clinical trials:

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma | NCT01319422

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | NCT05199311

Articles citing this

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Leukemia (2016) 0.80

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight (2016) 0.78

Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat Med (2016) 0.77

ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. J Clin Invest (2016) 0.76

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. Oncotarget (2017) 0.76

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer (2016) 0.75

Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology (2016) 0.75

Toward optimizing pomalidomide therapy in MM patients. Blood (2015) 0.75

Systematic evaluation of immune regulation and modulation. J Immunother Cancer (2017) 0.75

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. Front Immunol (2017) 0.75

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood (2017) 0.75

Articles cited by this

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Multiple myeloma. N Engl J Med (2011) 10.38

Identification of a primary target of thalidomide teratogenicity. Science (2010) 7.09

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol (2004) 3.37

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol (2013) 2.63

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45

Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res (1986) 2.37

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol (2013) 2.33

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood (2003) 2.22

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother (2008) 2.21

Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature (2014) 2.11

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood (2013) 2.06

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood (2014) 2.01

Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res (1986) 2.01

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood (2012) 1.94

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood (2012) 1.91

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood (2006) 1.88

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res (2009) 1.79

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77

Transcriptional regulation of the NKT cell lineage. Curr Opin Immunol (2013) 1.75

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood (2010) 1.66

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther (2003) 1.66

Ikaros enforces the costimulatory requirement for IL2 gene expression and is required for anergy induction in CD4+ T lymphocytes. J Immunol (2007) 1.61

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58

IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood (2011) 1.43

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med (2014) 1.30

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood (2014) 1.22

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis (2003) 1.13

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol (2013) 1.07

Ikaros silences T-bet expression and interferon-gamma production during T helper 2 differentiation. J Biol Chem (2009) 1.05

Pomalidomide. Blood (2013) 0.97

Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide. Immunology (2013) 0.91

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia (2014) 0.87

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol (2014) 0.87

Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia. Sci Transl Med (2013) 0.86

Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol Hematol (2013) 0.83

Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Crit Rev Oncol Hematol (2013) 0.82